Insider Selling: Replimune Group (NASDAQ:REPL) Insider Sells $52,065.00 in Stock

Replimune Group, Inc. (NASDAQ:REPL) insider Christopher Sarchi sold 6,500 shares of the stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $8.01, for a total value of $52,065.00. Following the transaction, the insider directly owned 151,588 shares of the company’s stock, valued at approximately $1,214,219.88. This trade represents a 4.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Replimune Group Price Performance

Shares of NASDAQ REPL opened at $5.89 on Thursday. The stock has a fifty day simple moving average of $7.59 and a two-hundred day simple moving average of $7.90. Replimune Group, Inc. has a 1-year low of $2.68 and a 1-year high of $13.24. The firm has a market cap of $486.34 million, a price-to-earnings ratio of -1.71 and a beta of 0.74. The company has a current ratio of 5.60, a quick ratio of 5.60 and a debt-to-equity ratio of 0.33.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported ($0.77) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.08. Analysts anticipate that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Institutional Investors Weigh In On Replimune Group

A number of institutional investors and hedge funds have recently made changes to their positions in the business. ProShare Advisors LLC raised its position in shares of Replimune Group by 10.3% in the fourth quarter. ProShare Advisors LLC now owns 16,116 shares of the company’s stock worth $157,000 after buying an additional 1,505 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Replimune Group by 4.7% in the third quarter. JPMorgan Chase & Co. now owns 38,016 shares of the company’s stock worth $159,000 after buying an additional 1,712 shares in the last quarter. Ballentine Partners LLC raised its position in shares of Replimune Group by 7.8% in the fourth quarter. Ballentine Partners LLC now owns 23,665 shares of the company’s stock worth $230,000 after buying an additional 1,721 shares in the last quarter. BNP Paribas Financial Markets raised its position in shares of Replimune Group by 37.5% in the second quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock worth $64,000 after buying an additional 1,879 shares in the last quarter. Finally, NEOS Investment Management LLC raised its position in shares of Replimune Group by 5.0% in the third quarter. NEOS Investment Management LLC now owns 42,966 shares of the company’s stock worth $180,000 after buying an additional 2,060 shares in the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on REPL shares. Piper Sandler increased their price objective on Replimune Group from $13.00 to $14.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Wedbush increased their target price on Replimune Group from $18.00 to $19.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Replimune Group in a research report on Monday, December 29th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $10.00.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.